Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer
Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer
复制标题
DOI：
10.1111/iju.12707
复制
发表时间：
2015-05-01
影响因子：
2.6
通讯作者：
Ueda, Takeshi
中科院分区：
文献类型：
--
作者：
Kobayashi, Masayuki;Hatano, Kazuo;Ueda, Takeshi
目的 探讨新辅助联合雄激素剥夺治疗和金标记植入调强放射治疗中、高危前列腺癌的疗效。方法本研究是对2001年至2001年间根据美国国家综合癌症网络指南，接受雄激素剥夺治疗和金标记植入后接受调强放射治疗（76Gy）的325例中高危前列腺癌患者的回顾性研究。 2010.结果极高危患者的5年无远处转移生存率显着低于中危和高危患者（分别为82.6% vs 99.4%和96.5%；P
ObjectivesTo investigate the therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate- and high-risk prostate cancer.MethodsThis was a retrospective study of 325 patients with intermediate- or high-risk prostate cancer according to the National Comprehensive Cancer Network guidelines who underwent androgen-deprivation therapy and intensity-modulated radiation therapy (76Gy) after gold marker implantation between 2001 and 2010.ResultsThe 5-year distant metastasis-free survival rate was significantly lower for very high-risk patients than for intermediate- and high-risk patients (82.6% vs 99.4% and 96.5%, respectively; P